Navigation Links
Westaim announces 2008 first quarter results
Date:5/12/2008

CALGARY, May 12 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the first quarter ended March 31, 2008, it recorded a net loss of $6.9 million or 7 cents per share, on revenues of $5.2 million. In the same quarter last year, the company recorded a net loss of $6.7 million, or 7 cents per share, on revenues of $6.1 million.

Income from continuing operations was $3.2 million for the quarter compared to $1.9 million in the same period last year. The results include a loss from discontinued operations of $10.1 million, primarily reflecting a write-down of capital assets of $7.1 million and severance costs of $2.0 million at the Company's wholly owned subsidiary, iFire Technology Ltd., compared to a loss from discontinued operations of $8.6 million for the first quarter of 2007. The first quarter 2008 results also include a dilution gain of $6.0 million relating to the sale of a non-core wholly owned subsidiary, compared to a dilution gain of $4.5 million in the first quarter of 2007.

At March 31, 2008, Westaim had $38.2 million in consolidated cash and cash equivalents compared to $31.0 million at December 31, 2007. Westaim's cash position, excluding cash and cash equivalents held by its 74.5 per cent owned affiliate NUCRYST Pharmaceuticals Corp., was $14.2 million. In addition, Westaim held asset-backed commercial paper (ABCP) with an estimated fair value of $6.0 million.

Tomorrow, The Westaim Corporation is holding its Annual Meeting of Shareholders in Toronto, Canada at 10:00 a.m. EDT. The meeting will be webcast live and is available through the company website http://www.westaim.com. An archive of the webcast will be posted following the meeting.

The Westaim Corporation's investments include iFire Technology Ltd., and a 74.5 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Westaim's common shares are listed and on The Toronto Stock Exchange under the trading symbol WED.

A more detailed discussion of Westaim's 2008 first quarter results can be found at http://www.westaim.com and http://www.sedar.com.

THE WESTAIM CORPORATION

Financial Highlights

(unaudited)

(thousands of dollars except per share data)

-------------------------------------------------------------------------

Three Months Ended March 31

--------------------------------

Consolidated Statements of Operations 2008 2007

-------------------------------------------------------------------------

Revenue $ 5,209 $ 6,131

Income from continuing operations 3,227 1,899

Net loss (6,857) (6,700)

Net income (loss) per common share -

basic and diluted

Continuing operations 0.03 0.02

Net loss (0.07) (0.07)

Weighted average number of common

shares outstanding (thousands) 94,186 93,992

-------------------------------------------------------------------------

Three Months Ended March 31

--------------------------------

Segmented Information 2008 2007

-------------------------------------------------------------------------

Revenue from continuing operations

Nucryst Pharmaceuticals $ 5,209 $ 6,131

-------------------------------------------------------------------------

-------------------------------------------------------------------------

(Loss) income from continuing operations

Nucryst Pharmaceuticals $ (2,238) $ (2,178)

Other (including corporate costs) 5,465 4,077

-------------------------------------------------------------------------

Income from continuing operations $ 3,227 $ 1,899

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Consolidated Balance Sheets March 31, 2008 December 31, 2007

-------------------------------------------------------------------------

Cash and cash equivalents $ 38,222 $ 30,993

Current assets 50,155 51,561

Other assets 24,605 31,826

Current liabilities 6,482 8,461

Shareholders' equity 50,268 56,371


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Westaim Corporation update on status of short-term investments
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. Westaim announces 2007 third quarter results
4. Westaim reduces ABCP exposure
5. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
6. Westaim announces 2007 year-end results
7. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, ... and Chandler, Arizona. , Dr. Olson says the decision to support the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: